文献速递临床微生物分子诊断

Tardiomyces blankii(原Candida blankii)及相关物种流行病学:国际「Epiblankii」研究结果

Epidemiology of Tardiomyces blankii (formerly Candida blankii) and related species: results of the International "Epiblankii" Study.
PubMed 文献 · J Clin Microbiol · 2026-09-30

该研究通过两个监测网络收集2019至2025年Tardiomyces spp.分离株,对46株进行10种抗真菌药物体外药敏试验及全基因组SNP分析。共鉴定34株T. blankii、11株T. depauwii和1株T. digboiensis,临床分离株涉及29例感染/定植。结果显示唑类和棘白菌素类MIC值高,且阿尼芬净和卡泊芬净MIC升高但米卡芬净不升高。

要点

  • Tardiomyces spp.为被忽视的新发机会性酵母,常规鉴定困难,改进MALDI-TOF MS数据库可提升菌种区分能力。
  • 体外药敏显示唑类和棘白菌素类MIC值高,阿尼芬净和卡泊芬净MIC升高而米卡芬净不升高。
  • T. blankii遗传多样性较大而T. depauwii遗传多样性低,多数法国分离株形成独立分支。

核心结论

  • Tardiomyces spp.是耐药性升高的罕见人类致病酵母,准确的实验室鉴定对监测和临床管理至关重要。

研究设计与样本

  • 通过质谱鉴定国际网络(法国巴黎)和荷兰奈梅亨真菌学专业中心两个监测网络,回顾性收集2019至2025年至少鉴定出一株T. blankii的分离株及数据。
  • 对46株分离株进行10种抗真菌药物体外药敏试验,并行全基因组测序单核苷酸多态性分析评估遗传多样性。

主要发现

  • 2019至2025年MSI应用共251份谱图鉴定为T. blankii sensu lato,两个网络共获得46株分离株用于进一步分析。
  • 46株中鉴定出34株T. blankii、11株T. depauwii和1株T. digboiensis,临床分离株涉及29例感染/定植病例。
  • 药敏试验显示唑类和棘白菌素类MIC值高,阿尼芬净和卡泊芬净MIC升高但米卡芬净不升高。
  • T. depauwii分离株遗传多样性低,T. blankii分离株遗传变异大,多数法国分离株形成独立分支。

关键数值与推荐

  • 体外药敏试验涵盖10种抗真菌药物,唑类和棘白菌素类MIC值高。
  • 阿尼芬净和卡泊芬净MIC升高,米卡芬净MIC不升高。

临床怎么用

  • 改进MALDI-TOF MS数据库可显著提升Tardiomyces spp.的菌种鉴定能力,有助于区分T. blankii、T. depauwii和T. digboiensis。
  • 对高危患者中出现的罕见酵母应进行准确鉴定和药敏试验,以支持监测、流行病学和临床管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tardiomyces blankii (previously known as Candida blankii) is an understudied emerging fungal pathogen with an unusual susceptibility profile. The aim of this study was to improve our understanding of the epidemiology of Tardiomyces spp. Cases were collected through two surveillance networks. The first was the Mass Spectrometry Identification (MSI) international network (La Pitié-Salpêtrière Hospital, Paris, France), based on mass spectrometry to identify fungal pathogens. The second was Canisius-Wilhelmina Hospital, Center of Expertise for Mycology (Nijmegen, the Netherlands). MSI members who had identified at least one T. blankii isolate between 2019 and 2025 collected retrospective data and provided their isolates. In vitro antifungal susceptibility testing (AFST) was carried out for 10 antifungal drugs. Whole-genome sequencing single-nucleotide polymorphism analysis was conducted to assess genetic diversity. Over the period 2019-2025, 251 spectra submitted to the MSI application were identified as T. blankii sensu lato. From the two surveillance networks, 46 isolates were available for further analysis, leading to the identification of 34 T. blankii, 11 Tardiomyces depauwii, and 1 Tardiomyces digboiensis. Clinical isolates were related to 29 cases of infection/colonization. The AFST data showed high minimum inhibitory concentration (MIC) values for azoles and echinocandins. Interestingly, these isolates demonstrated elevated MICs for anidulafungin and caspofungin but not micafungin. A low genetic diversity was found in T. depauwii isolates, while T. blankii isolates showed considerable genetic variation, although most French isolates formed a distinct clade. Our study sheds light on these rare human-pathogenic yeast species that exhibit reduced susceptibility to antifungal drugs.IMPORTANCETardiomyces spp. (formerly classified as Candida blankii) are emerging opportunistic yeasts that remain poorly recognized in routine clinical microbiology. To improve our understanding of the epidemiology of Tardiomyces spp., we combined data from the Mass Spectrometry Identification international network (Paris, France) and the Center of Expertise for Mycology (Nijmegen, the Netherlands) with whole-genome sequencing and antifungal susceptibility testing. We show that improving MALDI-TOF MS databases markedly enhances species identification, allowing discrimination between Tardiomyces blankii, Tardiomyces depauwii, and Tardiomyces digboiensis. Our findings also identify at-risk patients, describe the antifungal susceptibility profiles of these emerging pathogens, and reveal distinct patterns of genetic diversity. As uncommon fungal pathogens are increasingly encountered in vulnerable patients, accurate laboratory identification is essential for surveillance, epidemiology, and clinical management. These results provide practical tools and new knowledge that will facilitate the recognition and monitoring of this neglected genus.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Paumier M, Spruijtenburg B, Normand A-C, et al. Epidemiology of Tardiomyces blankii (formerly Candida blankii) and related species: results of the International "Epiblankii" Study. J Clin Microbiol. 2026. PMID: 42813794. doi:10.1128/jcm.00419-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。